Cumambrin A prevents OVX-induced osteoporosis via the inhibition of osteoclastogenesis, bone resorption, and RANKL signaling pathways.
Zhou L, Liu Q, Hong G, Song F, Zhao J, Yuan J, Xu J, Tan RX, Tickner J, Gu Q, Xu J.
Zhou L, et al. Among authors: yuan j.
FASEB J. 2019 Jun;33(6):6726-6735. doi: 10.1096/fj.201800883RRR. Epub 2019 Feb 26.
FASEB J. 2019.
PMID: 30807230
Collectively, our results reveal that cumambrin A can suppress osteoclast formation, bone resorption, and RANKL-induced signaling pathways, suggesting that cumambrin A is a potential therapeutic agent for the treatment of osteoporosis.-Zhou, L., Liu, Q., Hong, G., Song, F., Zhao, …
Collectively, our results reveal that cumambrin A can suppress osteoclast formation, bone resorption, and RANKL-induced signaling pathways, …